Journal of psychiatric practice

Psychiatric Drug Research Shifts from Symptom Groups to Targeted Brain Circuits and Personalized Treatments

Updated

Abstract

Approximately 60% of patients with major depressive disorder respond to monoaminergic treatments.

  • Remission rates for major depressive disorder and other serious mental disorders remain modest despite over 100 approved psychiatric drugs.
  • Differential response patterns to treatments suggest a need for biologically informed patient stratification.
  • Contemporary psychopharmacology includes mechanisms beyond classic neurotransmitter modulation, such as synaptic plasticity and inflammatory pathways.
  • Advances in neuromodulation techniques indicate a shift towards understanding psychiatric illness in terms of neural networks rather than specific brain regions.
  • Developments in pharmacogenomics and artificial intelligence are contributing to the emerging field of precision psychiatry.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free